Victoria K. Woodcock

Author

Also Known As

Sangary Kathirgamakarthigeyan, V. Woodcock, V.K. Woodcock, Victoria K Woodcock, Victoria K. Woodcock, Victoria Woodcock, Woodcock, Victoria K

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

University of Oxford MRC Weatherall Institute of Molecular Medicine Centre for Human Genetics Churchill Hospital John Radcliffe Hospital

About

Victoria K. Woodcock is an author at University of Oxford specializing in medicine, radiation oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	1.1K
2	Immunology	2	2	460
3	Public Health	1	1	599
4	Epidemiology	1	1	599
5	Pathology	1	1	15

Victoria K. Woodcock

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study Lennard Y. W. Lee, Jean‐Baptiste Cazier, Thomas Starkey, The Lancet Oncology Primary Tumour SubtypeEpidemiologyCancer EpidemiologyCovid-19 PrevalenceMedicine	2020	599
Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma Benjamin P. Fairfax, Chelsea Taylor, Robert Watson, Nature Medicine Tumor ImmunologyCancer ImmunosurveillanceImmunologyMetastatic MelanomaImmune Checkpoint Inhibitor	2020	358
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma Mark R. Middleton, Cheryl McAlpine, Victoria K. Woodcock, Clinical Cancer Research	2020	254
First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity Sophie Postel‐Vinay, Karin H. Herbschleb, Christophe Massard, European Journal of Cancer Pharmacological StudyMedicineImmunologyUnexpected ToxicityEarly Termination	2019	102
IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma Chelsea Taylor, Robert Watson, Orion Tong, Nature Medicine	2022	68
Semaphorin 3A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells Mike Bogetofte Barnkob, Yale S. Michaels, Violaine André, Nature Communications	2024	22
First-in-human phase I dose escalation study of the Bromodomain and Extra-Terminal motif (BET) inhibitor BAY 1238097 in subjects with advanced malignancies Sophie Postel‐Vinay, Karin H. Herbschleb, Christophe Massard, European Journal of Cancer Malignant DiseaseMedicineInhibitor Bay 1238097PathologyExtra-terminal Motif	2016	15
CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade Gusztav Milotay, Martin Little, Robert Watson, Nature Medicine	2025	13
A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424 Victoria K. Woodcock, Sally Clive, Richard H. Wilson, British Journal of Cancer	2018	11

Page 1